Boston Scientific Makes $1.5 Billion Power Play on MiRus Heart Valve
Boston Scientific paid $1.5 billion for a roughly 34% stake in MiRus and an option to acquire the SIEGEL TAVR business, a potential fast path back into balloon‑expandable valves. The move hinges on clinical and regulatory milestones.












